The body of evidence suggesting a causative, initiating role of beta amyloid (Aβ) in the
pathogenesis of Alzheimer's disease (AD) is substantial. Yet, only a few anti-amyloid agents …

In the management of neurological diseases, the identification and quantification of axonal
damage could allow for the improvement of diagnostic accuracy and prognostic assessment …

Increased cerebrospinal fluid neurofilament light (NfL) is a recognized biomarker for
neurodegeneration that can also be assessed in blood. Here, we investigate plasma NfL as …

CSF biomarkers, including total-tau, neurofilament light chain (NfL) and amyloid-β, are
increasingly being used to define and stage Alzheimer's disease. These biomarkers can be …

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by
the loss of upper and lower motor neurons. Presently, three FDA-approved drugs are …

Frontotemporal dementia (FTD) is a neurodegenerative disease of growing interest, since it
accounts for up to 10% of middle-age-onset dementias and entails a social, economic, and …

Neurofilament light chain (NfL) is a long-awaited blood biomarker that can provide clinically
useful information about prognosis and therapeutic efficacy in multiple sclerosis (MS). There …

Importance Effects of antiamyloid agents, targeting either fibrillar or soluble monomeric
amyloid peptides, on downstream biomarkers in cerebrospinal fluid (CSF) and plasma are …

Background Neurofilament light chain protein (NfL) is a promising biomarker of
neurodegeneration. Objectives To determine whether plasma and CSF NfL (1) associate …

According to the Geroscience concept that organismal aging and age-associated diseases
share the same basic molecular mechanisms, the identification of biomarkers of age that can …